The Changing Landscape of Immuno-Oncology: Insights from an Industry Expert
In the latest episode of “Crowncast,” Crown Bioscience’s scientific podcast, we had the pleasure of speaking with Gera Goverse, Director of Immuno-Oncology at Crown Bioscience, about the fascinating and ever-evolving world of immuno-oncology. With decades of experience and a breadth of knowledge, Dr. Goverse provides valuable insights into the rapidly changing landscape of immuno-oncology.
Understanding Immuno-Oncology
Dr. Goverse began by giving our audience a brief overview of the immuno-oncology field, a ground-breaking approach to fighting cancer using the body's immune system. This field has seen massive change and growth, particularly with the FDA's recent approval of TIL therapy and a bi-specific antibody that directly targets immune cells.
Future Trends and Developments
One trend Dr. Goverse emphasized was the increasing combination of therapies, moving away from the previous approach of solely using immune checkpoint inhibitors. Instead, these are now used in tandem with chemotherapy and targeted therapies to provide a more effective result. She discussed the potential of CAR-T cells and how researchers are working to prevent these cells from reaching an exhausted state, thus enhancing their efficacy. She also touched on innovations such as modifying CAR-T cells with virus mechanisms to suppress HLA expression and reduce the risk of graft versus host responses.
The Role of the Tumor Microenvironment
Another critical point in Dr. Goverse’s conversation was the role of the tumor microenvironment (TME) in immune-oncology research. Understanding the TME's complexities aids in categorizing tumors as either "hot" or "cold," which then dictates the therapeutic approach, necessitating combinations when dealing with "cold" or immune-deficient tumors.
Advice for Researchers
When offering advice to research groups and companies developing new treatments for immuno-oncology, Dr. Goverse emphasized the benefits of stepping out of their bubbles and being open to insights and ideas from outside sources. A thorough understanding of their target patient group, coupled with precise characterization of their models, could potentially increase the chances of therapeutic success.
“Don't get stuck in your bubble, maybe, you know, think also outside the bubble,” she states, advocating the importance of community, collaboration, and the sharing of knowledge for progress in the fight against cancer.
The Future of Immuno-Oncology
Dr. Goverse's excitement about the future of immuno-oncology resonated profoundly with our listeners. With the rise of combination therapies and the ongoing research and development in the field, we are on the brink of some revolutionary breakthroughs.
“It's also very exciting that those combinations are showing more success now,” she says.
There is no doubt that immuno-oncology is changing the game in cancer treatment as we know it. The insights provided by Dr.Goverse serve as a stimulating primer for anyone interested in understanding the complexities and potential of this groundbreaking field.
